These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18831154)

  • 1. Ira Remsen, saccharin, and the linear model.
    Warner DJ
    Ambix; 2008 Mar; 55(1):50-61. PubMed ID: 18831154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining, regulating and using saccharin at the outset of the industrial food era (1888-1914).
    Guillem-Llobat X
    Appetite; 2012 Dec; 59(3):905-11. PubMed ID: 22967818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Artificial sweetening agents].
    Bickel MH
    Bibl Nutr Dieta; 1971; 16():29-37. PubMed ID: 4939748
    [No Abstract]   [Full Text] [Related]  

  • 4. Sugar substitutes. Americans opt for sweetness and lite.
    Henkel J
    FDA Consum; 1999; 33(6):12-6. PubMed ID: 10628311
    [No Abstract]   [Full Text] [Related]  

  • 5. Artificial sweetener as a historical window to culturally situated health.
    de la Peña C
    Ann N Y Acad Sci; 2010 Mar; 1190():159-65. PubMed ID: 20388147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Supreme Court, process patents, and medical innovation.
    Kesselheim AS
    N Engl J Med; 2009 Dec; 361(24):2303-6. PubMed ID: 19923562
    [No Abstract]   [Full Text] [Related]  

  • 7. The German model of chemical education in America: Ira Remsen at Johns Hopkins (1876-1913).
    Hannaway O
    Ambix; 1976 Nov; 23(3):145-64. PubMed ID: 11615603
    [No Abstract]   [Full Text] [Related]  

  • 8. Transferring innovation.
    Kesan JP
    Fordham Law Rev; 2009 Apr; 77(5):2169-223. PubMed ID: 19431909
    [No Abstract]   [Full Text] [Related]  

  • 9. Saccharin as a sugar surrogate revisited.
    Smith JC; Sclafani A
    Appetite; 2002 Apr; 38(2):155-60. PubMed ID: 12027377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New artificial sweeteners].
    Göttinger E
    Wien Med Wochenschr; 1974 Jun; 124(25):393-5. PubMed ID: 4601057
    [No Abstract]   [Full Text] [Related]  

  • 11. Law machines: scale models, forensic materiality and the making of modern patent law.
    Pottage A
    Soc Stud Sci; 2011 Oct; 41(5):621-43. PubMed ID: 22164718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patenting medical inventions.
    Noonan WD
    Pharos Alpha Omega Alpha Honor Med Soc; 1990; 53(3):6-11. PubMed ID: 2204943
    [No Abstract]   [Full Text] [Related]  

  • 13. [Brocades & Stheeman: from apothecary-manufacturer to pharmaceutical industry].
    Rinsema T
    Tijdschr Geschied Geneeskd Natuurwet Wiskd Tech; 1999; 22(1):23-33. PubMed ID: 21141303
    [No Abstract]   [Full Text] [Related]  

  • 14. The sugar industry, political authorities, and scientific institutions in the regulation of saccharin: Valencia (1888-1939).
    Guillem-Llobat X
    Ann Sci; 2011 Jul; 68(3):401-24. PubMed ID: 21999094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patents, profits, and the American people--the Bayh-Dole Act of 1980.
    Markel H
    N Engl J Med; 2013 Aug; 369(9):794-6. PubMed ID: 23984726
    [No Abstract]   [Full Text] [Related]  

  • 16. The tragic story of Dr. William Taggart.
    Lamacki WF
    CDS Rev; 2009; 102(3):26. PubMed ID: 19530469
    [No Abstract]   [Full Text] [Related]  

  • 17. Ira Remsen, Osler, the Flexner Report, and the full-time plan.
    Bryan CS; Kopel JJ; Sorin M
    Proc (Bayl Univ Med Cent); 2021 Mar; 34(4):532-536. PubMed ID: 34219950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutagenicity study of Remsen-Fahlberg saccharin and contaminants.
    Eckhardt K; King MT; Gocke E; Wild D
    Toxicol Lett; 1980 Nov; 7(1):51-60. PubMed ID: 6794189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A modest proposal: toward improved access to biotechnology research tools by implementing a broad experimental use exception.
    Hoffman DC
    Cornell Law Rev; 2004 May; 89(4):993-1043. PubMed ID: 15174465
    [No Abstract]   [Full Text] [Related]  

  • 20. Using market-exclusivity incentives to promote pharmaceutical innovation.
    Kesselheim AS
    N Engl J Med; 2010 Nov; 363(19):1855-62. PubMed ID: 21047231
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.